Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles

Scandinavian Journal of Immunology

Volumn 66, Issue 6, 2007, Pages 645-653

  Greer, C E ^a   Zhou, F ^a   Goodsell, A ^a   Legg, H S ^a   Tang, Z ^a   Zur Megede, J ^a   Uematsu, Y ^a   Polo, J M ^a   Vajdy, M ^a  

^a Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HN PROTEIN; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HAMSTER; IMMUNITY; IMMUNIZATION; LUNG; NONHUMAN; NOSE MUCOSA; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; REPLICON; SINDBIS VIRUS; TURBINATE; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS PARTICLE;

ADMINISTRATION, INTRANASAL; ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; HUMANS; IMMUNIZATION; INJECTIONS, INTRAMUSCULAR; MUCOUS MEMBRANE; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; REPLICON; RNA, VIRAL; SINDBIS VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 36248937626     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02019.x     Document Type: Article

References (55)

1. Glezen WP, Denny FW. Parainfluenza viruses. In : Evans AC, Kaslow D, eds. Viral Infections in Humans: Epidemiology and Control, 4th edn. New York : Plenum, 1997 : 551 67.
2. Chanock RM, Murphy BR, Collins PL. Parainfluenza viruses. In : Knipe DM, ed. Fields Virology. Philadelphia, PA : Lippincott Williams & Wilkins, 2001 : 1341 79.
3. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969 89 : 449 63.
4. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969 89 : 435 48.
5. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969 89 : 405 21.
6. Ottolini MG, Porter DD, Hemming VG, Prince GA. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol 2000 13 : 231 6.
7. Belshe RB, Hissom FK. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol 1982 10 : 235 42.
8. Skiadopoulos MH, Durbin AP, Tatem JM et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 1998 72 : 1762 8.
9. Schmidt AC, McAuliffe JM, Huang A et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000 74 : 8922 9.
10. Skiadopoulos MH, Tao T, Surman SR, Collins PL, Murphy BR. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 1999 14 : 18.
11. Coelingh KJ, Winter CC, Murphy BR et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986 60 : 90 6.
12. van Wyke Coelingh KL, Winter CC, Tierney EL, London WT, Murphy BR. Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 1988 157 : 655 62.
13. Haller AA, Miller T, Mitiku M, Coelingh K. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 2000 74 : 11626 35.
14. Spriggs MK, Murphy BR, Prince GA et al. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 1987 61 : 3416 23.
15. Durbin AP, Cho CJ, Elkins WR, Wyatt LS, Moss B, Murphy BR. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J Infect Dis 1999 179 : 1345 51.
16. Durbin AP, Wyatt LS, Siew J, Moss B, Murphy BR. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 1998 16 : 1324 30.
17. Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996 14 : 1451 8.
18. Ebata SN, Prevec L, Graham FL, Dimock K. Function and immunogenicity of human parainfluenza virus 3 glycoproteins expressed by recombinant adenoviruses. Virus Res 1992 24 : 21 33.
19. Ebata SN, Cote MJ, Kang CY, Dimock K. The fusion and hemagglutinin- neuraminidase glycoproteins of human parainfluenza virus 3 are both required for fusion. Virology 1991 183 : 437 41.
20. Polo JM, Dubensky TW. Virus-based vectors for human vaccine applications. Drug Discov Today 2002 7 : 719 27.
21. Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989 243 : 1188 91.
22. Polo JM, Belli BA, Driver DA et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A 1999 96 : 4598 603.
23. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997 239 : 389 401.
24. Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991 9 : 1356 61.
25. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 1993 67 : 6439 46.
26. Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004 22 : 1537 44.
27. MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 2000 74 : 914 22.
28. Gardner JP, Frolov I, Perri S et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol 2000 74 : 11849 57.
29. Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 2004 82 : 617 27.
30. McGhee J, Lamm M, Strober W. Mucosal immune responses: an overview. In : Ogra P, Lamm M, Bienenstock J, Mestecky J, Strober W, McGhee J, eds. Mucosal Immunology, 2nd edn. San Diego : Academic Press, 1999 : 485 506.
31. Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv Drug Deliv Rev 2001 51 : 127 41.
32. Collier AM, Clyde WA Jr. Model systems for studying the pathogenesis of infections causing bronchiolitis in man. Pediatr Res 1977 11 : 243 6.
33. Greer CE, Zhou F, Legg H et al. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 2006 25 : 481 9.
34. Stokes A, Tierney EL, Murphy BR, Hall SL. The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res 1992 25 : 91 103.
35. Perri S, Greer CE, Thudium K et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003 77 : 10394 403.
36. Kobinger GP, Feldmann H, Zhi Y et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006 346 : 394 401.
37. Barouch DH, Pau MG, Custers JH et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004 172 : 6290 7.
38. Sharpe S, Polyanskaya N, Dennis M et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 2001 82 : 2215 23.
39. Lodmell DL, Ewalt LC. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 2000 18 : 2394 8.
40. Belshe RB, Newman FK, Tsai TF et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004 189 : 462 70.
41. Belshe RB, Newman FK, Anderson EL et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 2004 190 : 2096 103.
42. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, Liljestrom P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 1997 13 : 1487 95.
43. Vajdy M, Veazey R, Tham I et al. Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus. J Infect Dis 2001 184 : 1007 14.
44. Gupta S, Janani R, Bin Q et al. Characterization of HIV-gag-specific IFNg-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 2005 79 : 7135 45.
45. Davis NL, West A, Reap E et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 2002 53 : 209 11.
46. Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 2002 169 : 3208 16.
47. Fleeton MN, Chen M, Berglund P et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001 183 : 1395 8 (Epub 2001 Mar 30).
48. Pan CH, Valsamakis A, Colella T et al. Inaugural Article: Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 2005 102 : 11581 8.
49. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004 6 : 275 83.
50. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 2000 7 : 1859 66.
51. Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002 13 : 553.
52. Velders MP, McElhiney S, Cassetti MC et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 2001 61 : 7861 7.
53. Vajdy M, Singh M, Ugozzoli M et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003 110 : 86 94.
54. Vajdy M, Baudner B, Giudice GD, O'Hagan DT. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin Immunol 2007 123 : 166 75.
55. Bachmann MF, Kalinke U, Althage A et al. The role of antibody concentration and avidity in antiviral protection. Science 1997 276 : 2024 7.